The essence of the OSUCCC resides in its 6 Research Programs and 18 Shared Resources. It is composed of 179 full members, 38 associate and 24 introductory associate members from 13 of the 18 University colleges. Its clinical facilities include the freestanding James Cancer Hospital (JCH) as well as Nationwide Children's Hospital and now OSU East Hospital where cancer care is provided to inner city residents. To coordinate and manage an organization of this magnitude, the University supports the position of a strong CCC Director, who reports directly to the chief academic officer of the University, the Executive Vice President and Provost. Organizational capabilities of the CCC have been considerably strengthened by President Gee's appointment of Dr. Caligiuri as CEO of The James Cancer Hospital;his reporting to the President of the University, as well as his new membership on the President's Cabinet, and his continued membership on the Medical Center Executive Committee. In this capacity, Dr. Caligiuri privately meets at least monthly with President Gee, twice monthly with Provost Alutto, and at least weekly with Sr. VP Gabbe. This ensures that the Cancer Program's oversight planning and evaluation are in place and integrated within the University's strategic initiatives. These meetings assure cancer representation in the major initiatives across the University and the health system, and keep the President, Provost and Sr. VP adequately advised of all activity within the OSUCCC, including The JCH. In a large and diverse university, this organizational structure allows the Director to take maximum advantage of OSU's strengths and capabilities in promoting the cancer program agenda.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601800
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$39,608
Indirect Cost
$13,636
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Panfil, Amanda R; Al-Saleem, Jacob; Howard, Cory M et al. (2018) Stability of the HTLV-1 Antisense-Derived Protein, HBZ, Is Regulated by the E3 Ubiquitin-Protein Ligase, UBR5. Front Microbiol 9:80

Showing the most recent 10 out of 2602 publications